9 Worries To Ask Around PD0325901

boulardii MAPK inhibitor treatment. The primary outcome was the incidence of diarrhea defined as the percentage of patients developing a diarrhea. Diarrhea was defined as an increase in the frequency of bowel movements (>3/day) or decrease in stool consistency (Bristol stool scale 5 or 6). Secondary outcomes were: i) the onset of diarrhea, which was defined as the time between the inclusion of the patient and the onset of diarrhea; ii) the duration of diarrhea, which was defined as the number of days with diarrhea (the end of the diarrhea was defined as the moment when consistency (Bristol stool scale GRB10 13C UBT. Table 1 Efficacy of Treatment and Severity of Diarrhea The sample size was calculated using the following formula N=Z2��[p��(1-P)]/E2=174 where N is the sample size, Z the confidence interval (=1.96), E the sampling error (=0.05) and P the incidence of AAD (=0.13). Data analysis was performed using SPSS 11.5 statistical software (Softonic; Softonic International S.A., http://en.softonic.com/s/spss-11.5-statistical-software-free-download). The onset time and duration of diarrhea were analyzed using two-tailed t-tests; psee more while in the control group 26/92 (28.3%) patients had diarrhea (p the treatment group was 6.25��1.24 days, what was later than in the control group (4.05��1.11 days; p